Corporate News 29.10.2025 / 14:00 CET/CEST
OHB SE (ISIN: DE0005936124, Prime Standard) has acquired a further 30 % of shares in MT Aerospace AG, thereby becoming the sole shareholder in the company. MT Aerospace is a leading international aerospace company and has been part of the OHB Group since 2005.
“The full takeover of shares in MT Aerospace AG underlines both our confidence in the company's established growth path and in the very positive development of the global launch vehicle market. With its products and services, the company has been a reliable partner for decades, not only for the European aerospace industry, but also for the defense industry. We are convinced that our position as the single shareholder will make it easier for us to strengthen our position in the growing defense market," states Marco Fuchs, CEO of OHB SE.
The more than 500 employees develop, manufacture and test components for institutional and commercial launch vehicle programs, for aircraft, satellites and for applications in the defense industry. The company is Germany's largest supplier to the European Ariane 6 program. With a share of over 10 percent of the work packages for the Ariane 6 launch vehicle, the company is making a significant contribution to securing European access to space.
29 October 2025
PharmaSGP Holding SE FUTRUE increases adequate cash compensation under the squeeze-out
Corporate News
Gräfelfing, October 28, 2025 – Under agenda item 1 of the extraordinary general meeting of PharmaSGP Holding SE convened for October 31, 2025, the Management Board and Supervisory Board propose, at the request of FUTRUE GmbH, to transfer the shares of the remaining shareholders (minority shareholders) of PharmaSGP Holding SE to FUTRUE GmbH as the main shareholder in return for an adequate cash compensation in accordance with Sections 327a et seq. of the German Stock Corporation Act (AktG) (so-called squeeze-out).
The adequate cash compensation was originally set by FUTRUE GmbH at EUR 29.33 per PharmaSGP share. In view of the developments of the capital market and the business performance of PharmaSGP Holding SE in the meantime, ValueTrust, as a neutral expert, has updated its expert opinion. In light of this, FUTRUE GmbH has decided to increase the adequate cash compensation from EUR 29.33 to EUR 30.64 per share and has notified the Management Board of PharmaSGP Holding SE of this increase today.
Due to these developments, the Management Board and Supervisory Board have today amended their resolution proposal on agenda item 1 of the extraordinary general meeting on October 31, 2025, so that it now provides for an adequate cash compensation of EUR 30.64 per share.
The amended resolution proposal and other related documents, in particular, a supplement to the transfer report of FUTRUE GmbH explaining and justifying the adequacy of the adjusted cash compensation, as well as updated statements by the neutral expert and the court-appointed expert auditor, are available on the PharmaSGP Holding SE website under the heading “General Meeting.”
Further, an updated proxy form for instructing the company's proxies, which refers to the amended proposal, is available on the PharmaSGP Holding SE website under the heading “General Meeting.”
ABOUT PHARMASGP HOLDING SE
PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.
The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan®, Formigran®, Spalt® and Kamol®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of €118.8 million at an adjusted EBITDA margin of 31.3%.
Gräfelfing, October 28, 2025 – Under agenda item 1 of the extraordinary general meeting of PharmaSGP Holding SE convened for October 31, 2025, the Management Board and Supervisory Board propose, at the request of FUTRUE GmbH, to transfer the shares of the remaining shareholders (minority shareholders) of PharmaSGP Holding SE to FUTRUE GmbH as the main shareholder in return for an adequate cash compensation in accordance with Sections 327a et seq. of the German Stock Corporation Act (AktG) (so-called squeeze-out).
The adequate cash compensation was originally set by FUTRUE GmbH at EUR 29.33 per PharmaSGP share. In view of the developments of the capital market and the business performance of PharmaSGP Holding SE in the meantime, ValueTrust, as a neutral expert, has updated its expert opinion. In light of this, FUTRUE GmbH has decided to increase the adequate cash compensation from EUR 29.33 to EUR 30.64 per share and has notified the Management Board of PharmaSGP Holding SE of this increase today.
Due to these developments, the Management Board and Supervisory Board have today amended their resolution proposal on agenda item 1 of the extraordinary general meeting on October 31, 2025, so that it now provides for an adequate cash compensation of EUR 30.64 per share.
The amended resolution proposal and other related documents, in particular, a supplement to the transfer report of FUTRUE GmbH explaining and justifying the adequacy of the adjusted cash compensation, as well as updated statements by the neutral expert and the court-appointed expert auditor, are available on the PharmaSGP Holding SE website under the heading “General Meeting.”
Further, an updated proxy form for instructing the company's proxies, which refers to the amended proposal, is available on the PharmaSGP Holding SE website under the heading “General Meeting.”
ABOUT PHARMASGP HOLDING SE
PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.
The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan®, Formigran®, Spalt® and Kamol®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of €118.8 million at an adjusted EBITDA margin of 31.3%.
09 October 2025
artnet AG: Leonardo Art Holdings GmbH submits specified squeeze-out request and sets cash compensation for the transfer of the shares held by the minority share-holders of artnet AG at EUR 11.16
Corporate News
New York/Berlin, October 8, 2025 – Leonardo Art Holdings GmbH (“Main Shareholder”) today confirmed and specified its request to the management board of artnet AG (“Company”) dated August 19, 2025, for the transfer of the shares of the remaining shareholders of the Company (“Minority Shareholders”) to the Main Shareholder against payment of an adequate cash compensation in accordance with Sections 327a et seq. of the German Stock Corporation Act (“Squeeze-Out”).
The Main Shareholder has informed the Company’s management board that it holds approximately 95.42% of the Company’s share capital as of today following the completion of its public takeover and delisting offer and has set the adequate cash compensation for the transfer of the shares of the Minority Shareholders at EUR 11.16 per no-par value registered share of the Company. The court-appointed expert auditor responsible for reviewing the adequacy of the cash compensation has confirmed the adequacy of the cash compensation determined by the Main Shareholder.
The squeeze-out resolution of the Company’s shareholders meeting shall be passed at an extraordinary general meeting of the Company, which is expected to take place on November 20, 2025 in Berlin in the form of a physical shareholders’ meeting.
The Squeeze-Out will take effect once the squeeze-out resolution has been passed by the Company’s shareholders meeting and registered with the commercial register. Upon registration of the squeeze-out resolution with the commercial register, all shares held by Minority Shareholders in the Company will be transferred to the Majority Shareholder.
New York/Berlin, October 8, 2025 – Leonardo Art Holdings GmbH (“Main Shareholder”) today confirmed and specified its request to the management board of artnet AG (“Company”) dated August 19, 2025, for the transfer of the shares of the remaining shareholders of the Company (“Minority Shareholders”) to the Main Shareholder against payment of an adequate cash compensation in accordance with Sections 327a et seq. of the German Stock Corporation Act (“Squeeze-Out”).
The Main Shareholder has informed the Company’s management board that it holds approximately 95.42% of the Company’s share capital as of today following the completion of its public takeover and delisting offer and has set the adequate cash compensation for the transfer of the shares of the Minority Shareholders at EUR 11.16 per no-par value registered share of the Company. The court-appointed expert auditor responsible for reviewing the adequacy of the cash compensation has confirmed the adequacy of the cash compensation determined by the Main Shareholder.
The squeeze-out resolution of the Company’s shareholders meeting shall be passed at an extraordinary general meeting of the Company, which is expected to take place on November 20, 2025 in Berlin in the form of a physical shareholders’ meeting.
The Squeeze-Out will take effect once the squeeze-out resolution has been passed by the Company’s shareholders meeting and registered with the commercial register. Upon registration of the squeeze-out resolution with the commercial register, all shares held by Minority Shareholders in the Company will be transferred to the Majority Shareholder.
Subscribe to:
Comments (Atom)